A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010

Mills, Katherine T.; Xu, Yu; Zhang, Weidong; Bundy, Joshua D; Chen, Chung-Shiuan; Kelly, Tanika N.; Chen, Jing; He, Jiang

doi:10.1038/ki.2015.230

Cited by 705 publications

(561 citation statements)

References 44 publications

(49 reference statements)

Supporting

Mentioning

510

Contrasting

Unclassified

Order By: Relevance

“…1,2) It is defined based on the presence of kidney damage or a glomerular filtration rate (GFR) < 60 mL/minute per 1.73 m 2 for ≥ 3 months, irrespective of cause. CKD is closely related to cardiovascular disease, such as atrial fibrillation and heart failure.…”

Section: Hronic Kidney Disease (Ckd) Is a Rapidly Increasingmentioning

confidence: 99%

Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages?

Zhou

Zhu

et al. 2017

Int. Heart J.

View full text Add to dashboard Cite

SummaryThe benefits of implantable cardioverter defibrillator (ICD) implantation in chronic kidney disease (CKD) patients with high sudden cardiac death (SCD) risk are uncertain. To clarify the effects of receiving an ICD in CKD patients, we conducted this meta-analysis to identify the effects of ICDs on patients with CKD, including those on dialysis. We searched the Cochrane library, EMBASE, PubMed, and clinical trials for studies published before July 2016. Eleven studies including 20,196 CKD patients were considered for inclusion. The pooled analysis suggested that patients with an estimated glomerular filtration rate (eGFR) < 60 mL/minute/1.73 m 2 would benefit from receiving treatments with ICDs compared with patients without an ICD device (aHR = 0.77; 95% confidence interval [CI], 0.63 to 0.95). This is the first report of a subgroup analysis on the survival rate of ICD implantation in CKD patients according to an eGFR group. The subgroup analysis indicated a similar protective association of ICDs in stage 3 CKD patients (aHR = 0.71; 95%CI, 0.61 to 0.82) compared with the control group. However, there was no significant improvement in all-cause mortality in stage 4 CKD patients (aHR = 1.02; 95%CI, 0.75 to 1.37) or stage 5 CKD patients (aHR = 0.80; 95%CI, 0.60 to 1.31). This is the first meta-analysis reporting that ICD implantation reduces all-cause mortality in stage 3 CKD patients. However, the data do not indicate there is any benefit to ICD implantation in stage 4 or 5 CKD patients. (Int Heart J 2017; 58: 371-377)

show abstract

Section: Hronic Kidney Disease (Ckd) Is a Rapidly Increasingmentioning

confidence: 99%

Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages?

Zhou

Zhu

et al. 2017

Int. Heart J.

View full text Add to dashboard Cite

show abstract

“…There are 1.8 million patients with end-stage renal disease (ESRD) around the world that should be treated with renal replacement therapy including hemodialysis, peritoneal dialysis or kidney transplant (1). By the end of 2014, 27 457 dialysis patients were found in Iran (2).…”

Section: Introductionmentioning

confidence: 99%

Comparison of two interventions of increased blood flow rate and high-flux filters on hemodialysis adequacy and complications; a quasi-experimental study

Shahdadi¹,

Balouchi²,

Haghighi³

2017

J Renal Inj Prev

View full text Add to dashboard Cite

Dialysis should be a safe procedure with less complications. It should improve physical state of the patients. High dialysis adequacy should also be taken into account in dialysis procedure. Thereby, the present study recommended dialysis with increased blood flow rate with higher adequacy and less complications compared to routine dialysis despite insignificant difference in dialysis adequacy and complications between increased blood flow intervention and high-flux hemodialysis. Nevertheless, increased blood flow intervention increased dialysis adequacy. For this purpose, this intervention was preferred over high-flux hemodialysis. Introduction: Various parameters such as increased blood flow and high flux filter increase dialysis adequacy. Each parameter is associated with specific complications. Objective: The aim of this study was comparison of two interventions of increased blood flow rate and high-flux filter on hemodialysis adequacy and complications. Please cite this paper as: Patients and Methods:This was a single-group quasi-experimental before-and-after intervention study. Twenty-two patients undergoing dialysis three times a week in the last 6 months consented to participate in the study. The participants were selected using random sampling method. They were reevaluated prior to dialysis and every 30 minutes until the end of each hemodialysis session using dialysis complication checklist. Dialysis adequacy was measured at the end of the fourth session for each patient. Results: The paired t test results showed a significant increase in dialysis adequacy in dialysis with increased blood flow and dialysis with high flux filter (high-flux hemodialysis) compared to routine dialysis (P = 0.01). A significant increase was found in incidence of muscular cramp in dialysis with increased blood flow compared to routine dialysis based on McNemar's statistical test (P = 0.02). Conclusion: Dialysis adequacy improved in both increased blood flow intervention and highflux hemodialysis compared to routine dialysis. On the other hand, increased blood flow intervention was associated with less complications than high-flux hemodialysis. In addition, increased blood flow intervention was more efficient and safer than high-flux hemodialysis.

show abstract

mentioning

confidence: 99%

“…8 Mills et al 8 included 33 original population-based studies totaling .920,000 people, of whom 81% were from high-income countries. Mills et al 8 analyzed study-level (and not individual patient-level) data to provide pooled estimates of CKD prevalence for high-income and low/middle-income countries separately while stratifying by age and sex. Seven cohorts were included in both the work by Brück et al 7 and the work by Mills et al, 8 accounting for 39% of the total study population in the work by Brück et al 7 Using the same definition for CKD but a different standard global population for age and sex standardization, Mills et al 8 found an overall age-adjusted CKD stages 1-5 prevalence in high-income countries that was in line with that in the work by Brück et al 7 : 10.1% in men and 12.1% in women; for CKD stages 3-5, it was somewhat higher (5.4% and 8.6% for men and women, respectively).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Unlocking the Value of Variation in CKD Prevalence

Black

Veer

2015

JASN

View full text Add to dashboard Cite

in the acetazolamide-treated mice with lithium-induced NDI. de Groot et al. 3 also found that acetazolamide treatment of mice with lithium-induced NDI reduces inulin clearance, reduces the cortical expression of the sodium/hydrogen exchanger 3, and reduces the increase in urinary prostaglandin E 2 observed in mice with lithium-induced NDI.de Groot et al. 3 concluded that the reduction in polyuria after acetazolamide treatment was partially caused by a tubular-glomerular feedback response and reduced GFR. In addition, de Groot et al. 3 concluded that the tubular-glomerular feedback response and/or a direct effect on collecting duct principal or intercalated cells may be responsible for the reduction in urinary prostaglandin E 2 levels in mice with lithium-induced NDI and treated with acetazolamide and that this contributes to the amelioration of the lithium-induced NDI. Thus, de Groot et al. 3 made the novel observation that acetazolamide, by inhibiting CA, attenuates lithium-induced NDI in mice similar to thiazide/amiloride but with fewer adverse side effects. This study establishes the basis for a future clinical trial to determine if acetazolamide would be effective in treating people with lithium-induced NDI with equal efficacy but fewer side effects than thiazide/amiloride.Together, these two papers in JASN provide important and novel insight into the pathogenesis and potential therapy for NDI. They also emphasize the importance of fundamental research in renal physiology for providing novel insights that can serve as the inspiration and foundation of future translational or clinical studies to advance the treatment of NDI specifically and renal disease in general.

show abstract

A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010

Cited by 705 publications

References 44 publications

Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages?

Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages?

Comparison of two interventions of increased blood flow rate and high-flux filters on hemodialysis adequacy and complications; a quasi-experimental study

Unlocking the Value of Variation in CKD Prevalence

Contact Info

Product

Resources

About